Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Cofactor, nucleoside or nucleotide
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 5957
Molecular formula: C10H16N5O13P3
IUPAC: [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
Source: PC-ATP
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Energy nucleotide/extracellular signal; ingesting ATP is not direct delivery to muscle-cell cytoplasm.
Evidence and critical reading
Reported scientific and empirical uses
Replacement and nutritional context
Offered for performance and as a Super Shred ingredient; these are distinct contexts/formulations.
Human evidence
An 11-trained-man crossover study found a performance signal after 400 mg orally; other outcomes/studies differ. It does not establish injectable ATP/albuterol efficacy or safety.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
An 11-trained-man crossover study found a performance signal after 400 mg orally; other outcomes/studies differ. It does not establish injectable ATP/albuterol efficacy or safety.
An 11-trained-man crossover study found a performance signal after 400 mg orally; other outcomes/studies differ. It does not establish injectable ATP/albuterol efficacy or safety.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by A Single Dose of Oral ATP Supplementation Improves Performance and Physiological Response During Lower Body Resistance Exercise in Recreational Resistance-Trained Males.
400 mg · Single studied exposure
- Frequency
- One exposure per condition
- Duration
- Acute
- Route
- Oral
- Context
- 11 trained men; short-duration exercise outcome.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID29045315 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Studied oral amounts cannot be converted into parenteral doses. The commercial blend’s clinical interaction profile is not validated here.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
adenosine triphosphate · 81 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07833865 · The Effect of Light Therapy on Cellular Energy and Oxidative Stress in Healthy Adults and Type 1 Diabetic PatientsRegistry status: Not yet recruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT05926466 · BTZ-043 Dose Evaluation in Combination and SelectionRegistry status: CompletedLast update posted: October 5, 2026Query verification: October 16, 2026
NCT07784231 · The Use of Photobiomodulation in the Treatment of Spasticity After Stroke.Registry status: RecruitingLast update posted: September 1, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-ATP
PubChem adenosine triphosphate (CID 5957)
October 16, 2026
- PMID29045315
Freitas MC, Cholewa JM, Gerosa-Neto J, Gonçalves DC, Caperuto EC, Lira FS, Rossi FE.
October 16, 2026
- PMID38193939
Fambrini DL, Campos Neto EL, Ferreira Dos Santos C.
October 16, 2026
- SEARCH-PUBMED-atp
October 16, 2026